Trials / Unknown
UnknownNCT05447260
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis: a Multicenter, Prospective, Single-arm Clinical Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, prospective, single-arm study to assess safety and efficacy of Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Dosage based on platelet count |
Timeline
- Start date
- 2022-06-10
- Primary completion
- 2022-12-10
- Completion
- 2023-12-10
- First posted
- 2022-07-07
- Last updated
- 2022-07-07
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05447260. Inclusion in this directory is not an endorsement.